National cancer quality-control center and registry system
2013–Established the nationwide oncology quality-control network and annual cancer registry report, unifying care standards and advancing homogenized cancer care across China.

Grade III-A · National Cancer Center
Established
1958
Beds
2,300+
Annual Volume
1,000,000+
Beijing
China’s national flagship for cancer care, ranked No.1 in oncology for consecutive years in the Fudan hospital specialty ranking.
The Cancer Hospital, Chinese Academy of Medical Sciences — home of the National Cancer Center — is the “national team” of China’s cancer control system, integrating care, research, teaching and prevention, and carrying out national cancer registration, early detection and nationwide quality-control functions. Its oncology discipline has ranked first in the Fudan specialty reputation ranking for many consecutive years.
The hospital operates a complete disciplinary system — thoracic surgery, medical oncology, radiation oncology, gynecologic oncology, colorectal surgery and more — with routine MDT consultations, and leads the development of multiple national diagnostic and treatment guidelines.
01National quality control and guideline setter
As host of the National Cancer Center, it leads the publication of national oncology development reports and multiple tumor-specific treatment standards — its pathways represent national-level benchmarks.
02A hub for complex cases and clinical research
It receives large numbers of complex referrals nationwide and leads more registered clinical studies than any other cancer hospital in China — patients gain early access to frontier treatments.
03Pan-tumor MDT system
Each tumor type has a standing MDT team where imaging, pathology, molecular diagnostics and treatment disciplines decide together — one-stop plan-making for international patients.
Established the nationwide oncology quality-control network and annual cancer registry report, unifying care standards and advancing homogenized cancer care across China.
Built a surgery-centered comprehensive care pathway for esophageal cancer integrating chemoradiotherapy and immunotherapy, with multiple results incorporated into national care standards.